Moderna, Inc. (NASDAQ: MRNA) reported second quarter 2023 earnings results today.
Total revenue dropped to $344 million from $4.7 billion in the same period last year, mainly due to a decrease in sales of the company’s COVID-19 vaccine.
Net loss was $1.4 billion, or $3.62 per share, compared to net income of $2.2 billion, or $5.24 per share, last year.
Product sales were $293 million, down 94% compared to last year, mainly due to lower sales volume. The company reported $0.3 billion in COVID-19 vaccine sales in Q2.
For FY2023, the company is expecting COVID-19 sales of $6-8 billion, dependent on US vaccination rates.
Most Popular
CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%
Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss
Key metrics from Nike’s (NKE) Q2 2025 earnings results
NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net
FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips
Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,
